Visit Our Blog
  • FDNA TELEHEALTH
  • Products
    • Face2Gene Labs
    • Face2Gene Clinic
  • About FDNA
  • News & Press
    • In The News
    • Press Releases
  • Contact
  • FDNA Insights

FDNA Insights

Categories
  • All
  • 2018
  • ACMG
  • Case Study
  • Events/Conferences
  • Face2Gene
  • Genomics
  • Pharma
  • Pharma
  • Phenotyping
  • Rare Diseases
  • Scientific Abstracts
  • Talks
  • Technology
  • Uncategorized
  • Videos
  • Webinar

FDNA’s Keynote at ePharma: Using Next-Generation Phenotyping For Precision Medicine Across the Pharma Value Chain

April 9, 2018

By Dekel Gelbman

Events/Conferences,Face2Gene,Pharma,Pharma,Talks

NOTE: This post is based on a presentation made at the March 2018 ePharma conference in New York City.

 

As with every element of the medical and scientific world, the pharmaceutical industry has nearly endless options for digital technology tools. The challenge becomes how to maximize those digital technologies during three critical stages: discovery, development, and commercialization.

Next-generation phenotyping (NGP), the process of capturing, structuring, and integrating complex clinical data into health analyses, is one such an optimization technique. NGP has a multiplier effect on the knowledge accessible through traditional digital technologies. By improving specificity, speed, drug efficacy, and cost efficiency, NGP is revolutionizing pharma.

 

DISCOVERY

First up is disease research. Current technologies offer the chance to identify disease-causing genetic variants and disease mechanisms, but genomics data alone can fall short of a definitive diagnosis. Candidate variants can be difficult to filter and prioritize, and if multiple pathogenic variants exist in a genome, current understanding of their functional consequences can blur any conclusions. There is an overwhelming amount of data available, but it’s not always parsable.

Deep phenotyping (gathering and analyzing a thorough patient phenotype) can resolve these uncertainties by improving patient stratification. Clustering patients narrows down candidate variants with high impact scores, and cohorts with the correlated phenotypes and genotypes can then be studied to understand disease pathways.

 

DEVELOPMENT

Once NGP improves the understanding of causal variants and disease mechanisms, it can also assist in drug development. Currently, digital technology is used for trial design and clinical trial recruitment, but determining clinical significance to segment patients is still challenging and costly and often ends in ineffective cohort selection.

 

Pharmaceutical companies need to mitigate the risk of failure through faster, cheaper and, most importantly, more precise patient recruitment. NGP supports segmentation of potential trial recruits into specific subsets of a disease based on variations in disease presentation, even analyzing which genetic variants are likely to be present in each patient, and can thus reduce unnecessary genetic testing, making patient screening faster and cheaper. Stratified trial groups also increase the chance of trial success, and once a drug is successful, companies can move to the all important commercial phase.

 

COMMERCIAL

Using the same genotypic and phenotypic analysis, clinicians can shorten the diagnostic odyssey, by increasing the potential recipient list and narrowing it based on likely responsiveness. NGS may be declining in cost, but it still falls short in diagnostic yield when used alone and can miss diagnoses or even misdiagnose a patient. Incorporating NGP will more precisely define potential responders, further increasing the value of a drug for targeted patients.

All told, NGP would propel precision medicine toward that 26 billion worldwide savings mark— a conservative estimate—all while improving the lives of the patients themselves.

More entries about Events/Conferences

Rare Diseases
 

A Rare Disease Day Reflection

Rare diseases affect roughly 30 million Americans, yet only 5 percent of the estimated 7,000 known rare diseases have cures Read more

Events/Conferences
 

What to Do and See at ASHG 2018

San Diego, CA – The FDNA team is excited to be back at the American Society of Human Genetics (ASHG) Read more

Events/Conferences
 

AI in Healthcare: Separating the Hype from the Hope

FDNA’s CEO Dekel Gelbman recently spoke to hundreds of leaders during the Stanford Big Data in Precision Health Summit. The Read more

Events/Conferences
 

FDNA and Face2Gene Featured at ESHG

  A flock of researchers from around the globe shared their findings in dysmorphology and molecular genetics at this year’s Read more

Events/Conferences
 

What to Do and See at ESHG

The European Society of Human Genetics (ESHG) 42nd Annual  Meeting 2018 MiCo – Milano Congressi · Milan, Italy · June Read more

Events/Conferences
 

The Road to Precision Medicine: Balancing Ethics and Efficiency

Artificial intelligence has increasingly become the basis for advancing precision medicine. Tomorrow, at the ReWork Deep Learning in Healthcare Summit Read more

Pharma
 

FDNA’s Keynote at ePharma: Using Next-Generation Phenotyping For Precision Medicine Across the Pharma Value Chain

NOTE: This post is based on a presentation made at the March 2018 ePharma conference in New York City.   Read more

Events/Conferences
 

What to Do and See at ACMG

The American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting 2018 Charlotte Convention Center · Charlotte, North Carolina · April 10-14, 2018 Read more

Events/Conferences
 

Greenwood Genetic’s Journey: Partnering to Improve Precision Medicine

In its 44 year history, Greenwood Genetic Center (GGC) has seen over 80,000 patient cases. That’s a lot of data. Read more

Events/Conferences
 

Happening at HIMMS: Precision Medicine Through Next-Generation Phenotyping—A Customer’s Journey

HIMSS Conference, Microsoft booth Thursday, March 7 3:40 PM PST Las Vegas, Nevada   As over 40,000 health IT professionals, Read more

Events/Conferences
 

FDNA Announces Genomics Collaborative® at a Global Innovation Summit

English | Spanish In a packed auditorium at Mexico City’s CENTRO University, FDNA’s Senior Director of Marketing, Jeff Daniels, announced Read more

Events/Conferences
 

Drug Delivery Partnership: Precision Medicine Drives Discovery, Development and Commercialization in Pharma

In an era of breakthrough advancements in healthcare, it is hard to believe that 90% of blockbuster medicines are only Read more

Events/Conferences
 

What to Do and See at ASHG

The American Society of Human Genetics 67th Annual Meeting (ASHG 2017) Orange County Convention Center · Orlando, Florida October 17-21, Read more

Events/Conferences
 

FDNA Presents Rare Disease Technologies at the 2017 Precision Medicine Summit at Boston Children’s Hospital

The Division of Genetics and Genomics Department of Medicine at Boston Children’s Hospital will present their exciting new Fall Precision Read more

Events/Conferences
 

Disorder: The Rare Disease Film Festival

Disorder: The Rare Disease Film Festival will be held October 2 & 3, 2017 in Boston, MA. This is a new event Read more

Events/Conferences
 

What to Do and See at ESHG 2017 in Copenhagen

Annual Clinical Genetics Meeting (ESHG 2017) Bella Center Copenhagen, Copenhagen, Denmark May 27-30, 2017 Copenhagen, Denmark – The time is yet again Read more

Rare Diseases
 

New Facial Analysis Discoveries for RASopathy Syndromes in the Year of Discovery

  In March, FDNA reached out to clinicians and patients globally as part of the Year of Discovery to collect Read more

Rare Diseases
 

FDNA Partners with Blueprint Genetics to Spotlight RASopathies During the Year of Discovery

FDNA’s Year of Discovery Initiative will spotlight a different genetic syndrome group each month as part of their mission to Read more

Events/Conferences
 

What to Do and See at ACMG 2017 in Phoenix, AZ

Annual Clinical Genetics Meeting (ACMG 2017) Phoenix Convention Center, Phoenix, Arizona March 21-25, 2017 Phoenix, Arizona – With ACMG just over Read more

Rare Diseases
 

FDNA Launches “Year of Discovery” for Rare Disease Day

FDNA Launches “Year of Discovery” for Rare Disease Day Boston-based health and tech start-up calls on patients and clinicians to share Read more

  • Contact Us
  • Privacy Policy
  • Terms of Use

Signup for News


* These fields are required.

© 2011-2021 FDNA INC. www.FDNA.com. All rights reserved.

Face2Gene is a search and reference tool provided for informational purposes and not intended to replace the clinician’s judgment or experience, nor should it be used to diagnose or treat medical conditions.